Medherant is a clinical-stage company developing innovative treatments using its novel transdermal drug delivery technology, the TEPI Patch, which is based on a proprietary adhesive developed by its scientists. The Company was founded by Professor David Haddleton and the University of Warwick in 2015 based on their world-leading expertise in bioadhesives and polymer chemistry.
The adhesive has a high drug loading capacity, so a smaller quantity of adhesive is needed to deliver a therapeutic dose; the patch can therefore be thinner and more flexible. It also enables excipients, such as permeation enhancers, to be included in the adhesive so the release of the drug from the patch can be tailored to achieve the desired product profile.
The adhesive also provides excellent adhesion, even in moist conditions. This means that the patch remains in contact with the skin throughout the dosing period, so the full dose is delivered. There is no leakage of adhesive from the patch so there is no unsightly black ring around its edge and no residue on the skin after removal.
Medherant undertakes feasibility studies for other companies to investigate whether their drugs can be formulated for transdermal delivery using the TEPI technology. Medherant welcomes enquires from companies interested in licensing its products for commercialisation or undertaking feasibility studies.
The adhesive has a high drug loading capacity, so a smaller quantity of adhesive is needed to deliver a therapeutic dose; the patch can therefore be thinner and more flexible. It also enables excipients, such as permeation enhancers, to be included in the adhesive so the release of the drug from the patch can be tailored to achieve the desired product profile.
The adhesive also provides excellent adhesion, even in moist conditions. This means that the patch remains in contact with the skin throughout the dosing period, so the full dose is delivered. There is no leakage of adhesive from the patch so there is no unsightly black ring around its edge and no residue on the skin after removal.
Medherant undertakes feasibility studies for other companies to investigate whether their drugs can be formulated for transdermal delivery using the TEPI technology. Medherant welcomes enquires from companies interested in licensing its products for commercialisation or undertaking feasibility studies.
Location: United Kingdom, England, Coventry
Employees: 11-50
Total raised: $10.78M
Founded date: 2015
Funding Rounds 3
| Date | Series | Amount | Investors |
| 04.04.2023 | - | $3.75M | Mercia Ass... |
| 11.12.2017 | - | $5.07M | - |
| 27.09.2016 | - | $1.95M | - |
Mentions in press and media 10
| Date | Title | Description |
| 04.04.2023 | Medherant Raises £3M in Funding | Medherant, a Coventry, UK-based biotechnology company advancing a testosterone patch for women with menopausal symptoms, raised £3M in funding. Mercia Asset Management made the investment. The company intends to use the funds to accelerate ... |
| 06.12.2022 | Mercia interim results 2023 – Chief Investment Officer’s Review | Investment activity |
| 11.12.2017 | Medherant Raises £3.8M in Funding | Medherant Limited, a University of Warwick (UK) spinout company developing an innovative transdermal drug delivery patch technology, raised £3.8m in funding. The round was led by existing investor Mercia Technologies PLC, which has invested... |
| 11.12.2017 | UK medtech startup Medherant raises £3.8 million in new funding | Medherant, a medical technology company spun out from the University of Warwick in the UK, has raised £3.8 million in new capital. Mercia Technologies led the round by investing £2.5 million, bringing its stake in the company to 32.4%. Medh... |
| 11.12.2017 | Mercia invests £2.5m as part of £3.8m funding round in Medherant | Mercia Technologies PLC, the national investment group focused on the funding and scaling of innovative technology businesses with high growth potential from the UK regions, is pleased to announce that it has invested £2.5million as part of... |
| 17.11.2017 | Medherant wins Excellence in Science & Technology Award | Medherant, a Mercia Technologies PLC portfolio company, won the Excellence in Science & Technology Award at the Coventry Telegraph Business Awards last night. The Awards are a celebration of companies in Coventry and Warwickshire which ... |
| 28.06.2017 | Medherant expands management team as it moves into clinical development of its revolutionary TEPI Patch® | Medherant, a developer of novel transdermal drug delivery patch technology, has appointed Sally Waterman as Chief Operating Officer (COO), Angus Hone as Chief Financial Officer (CFO) and Sheryl Caswell as Head of Clinical Development. These... |
| 12.06.2017 | Medherant shortlisted for Royal Society of Chemistry Emerging Technologies competition | Medherant, which joined Mercia Technologies’ portfolio of direct investments in September 2016, has been selected for its versatile and easy to use, solvent-free transdermal drug delivery platform, the TEPI Patch®, which is based upon a nov... |
| 27.09.2016 | MedTech startup Medherant closes £1.5M financing round for its transdermal drug delivery platform | Medherant, a spin-out of the University of Warwick (UK) developing a novel transdermal drug delivery patch technology, has completed a funding round worth £1.5 million, including a direct investment of £650,000 from Mercia Technologies PLC.... |
| - | Medherant | “Medherant is creating a sustainable, next-generation transdermal drug delivery patch company that creates value for patients, partners and investors.” |